HomeInsightsStock Comparison

Aurobindo Pharma Ltd vs Cohance Lifesciences Ltd Stock Comparison

Aurobindo Pharma Ltd vs Cohance Lifesciences Ltd Stock Comparison

Last Updated on: Jul 17, 2025

Key Highlights

  • The Latest Trading Price of Aurobindo Pharma Ltd is ₹ 1161 as of 17 Jul 13:17.
  • The P/E Ratio of Aurobindo Pharma Ltd changed from 8.5 on March 2020 to 20.1 on March 2024 . This represents a CAGR of 18.78% over 5 yearsThe P/E Ratio of Cohance Lifesciences Ltd changed from 8.1 on March 2020 to 57.3 on March 2024 . This represents a CAGR of 47.89% over 5 years.
  • The Market Cap of Aurobindo Pharma Ltd changed from ₹ 24202 crore on March 2020 to ₹ 63835 crore on March 2024 . This represents a CAGR of 21.41% over 5 yearsThe Market Cap of Cohance Lifesciences Ltd changed from ₹ 2564 crore on March 2020 to ₹ 17223 crore on March 2024 . This represents a CAGR of 46.37% over 5 years.
  • The revenue of Aurobindo Pharma Ltd for the Mar '25 is ₹ 8516 crore as compare to the Dec '24 revenue of ₹ 8137 crore. This represent the growth of 4.66% The revenue of Cohance Lifesciences Ltd for the Mar '25 is ₹ 412.59 crore as compare to the Dec '24 revenue of ₹ 322.86 crore. This represent the growth of 27.79%.
  • The ebitda of Aurobindo Pharma Ltd for the Mar '25 is ₹ 1894 crore as compare to the Dec '24 ebitda of ₹ 1736 crore. This represent the growth of 9.08% The ebitda of Cohance Lifesciences Ltd for the Mar '25 is ₹ 84.13 crore as compare to the Dec '24 ebitda of ₹ 133.41 crore. This represent the decline of -36.94%.
  • The net profit of Aurobindo Pharma Ltd changed from ₹ 569.71 crore to ₹ 902.83 crore over 8 quarters. This represents a CAGR of 25.89% The net profit of Cohance Lifesciences Ltd changed from ₹ 120.59 crore to ₹ 38.73 crore over 8 quarters. This represents a CAGR of -43.33% .
  • The Dividend Payout of Aurobindo Pharma Ltd changed from 9.37 % on March 2020 to 13.49 % on March 2024 . This represents a CAGR of 7.56% over 5 yearsThe Dividend Payout of Cohance Lifesciences Ltd changed from 23.57 % on March 2020 to 0 % on March 2024 . This represents a CAGR of -100.00% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Aurobindo Pharma Ltd

  • Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in 26th December 1986 as a private limited company.
  • Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it.
  • APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations.
  • The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products.
  • APL is running with 24 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities.

About Cohance Lifesciences Ltd

  • Suven Pharmaceuticals Limited (SPL) is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
  • The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Suven Pharmaceuticals Limited was incorporated on 6 November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
  • The Company has established core competencies in cyanation and heterocyclic chemistry, covering pyrimidines, quinolones, thiazoles, and imidazoles.

Aurobindo Pharma Ltd News Hub

News

Aurobindo Pharma Ltd drops for fifth straight session

Aurobindo Pharma Ltd fell for a fifth straight session today. The stock is quoting at Rs 1...

Read more

11 Jul 2025 13:35

News

CuraTeQ Biologics receives European marketing authorization for biosimilar Dazublys'

CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma, has obt...

Read more

02 Jul 2025 18:36

News

Lyfius Pharma re-starts production at its Penicillin-G manufacturing facility

Aurobindo Pharma announced that its wholly owned step-down subsidiary, Lyfius Pharma has r...

Read more

30 Jun 2025 09:29

News

Aurobindo Pharma Ltd spurts 0.22%, up for fifth straight session

Aurobindo Pharma Ltd is up for a fifth straight session today. The stock is quoting at Rs ...

Read more

26 Jun 2025 13:00

News

Aurobindo Pharma gets UK MHRA approval for neutropenia treatment drug Dyrupeg

Dyrupeg contains the active substance pegfilgrastim and is a biological medicine. It is a ...

Read more

25 Jun 2025 12:51

News

CuraTeQ Biologics receives UK MHRA approval for biosimilar Dyrupeg'

Aurobindo Pharma announced that CuraTeQ Biologics s.r.o., a wholly owned step-down subsidi...

Read more

24 Jun 2025 19:01

Cohance Lifesciences Ltd News Hub

News

Cohance Lifesciences to announce Quarterly Result

Cohance Lifesciences will hold a meeting of the Board of Directors of the Company on 13 Au...

Read more

28 Jun 2025 09:56

News

Cohance Lifesciences to hold AGM

Cohance Lifesciences announced that the 7th Annual General Meeting(AGM) of the company wil...

Read more

27 Jun 2025 15:41

News

Cohance Lifesciences' API Unit-IV clears USFDA inspection

Cohance Lifesciences has received the Establishment Inspection Report (EIR) from the Unite...

Read more

26 May 2025 08:46

News

Suven Pharmaceuticals allots 12.80 cr equity shares

Suven Pharmaceuticals has allotted 12,80,02,184 equity shares of the Company of face value...

Read more

09 May 2025 09:58

News

Suven Pharmaceuticals renamed as Cohance Lifesciences

Suven Pharmaceuticals announced that the Ministry of Corporate Affairs, Government of Indi...

Read more

08 May 2025 09:39

News

Suven Pharmaceuticals receives regulatory nod for scheme of amalgamation

Suven Pharmaceuticals announced that it has received final approval from the Department of...

Read more

26 Apr 2025 12:56

SWOT Analysis Of Cohance Lifesciences Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Aurobindo Pharma Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Cohance Lifesciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Aurobindo Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Aurobindo Pharma Ltd and Cohance Lifesciences Ltd

Which company has a larger market capitalization, Aurobindo Pharma Ltd or Cohance Lifesciences Ltd?

Market cap of Aurobindo Pharma Ltd is 67,552 Cr while Market cap of Cohance Lifesciences Ltd is 40,643 Cr

What are the key factors driving the stock performance of Aurobindo Pharma Ltd and Cohance Lifesciences Ltd?

The stock performance of Aurobindo Pharma Ltd and Cohance Lifesciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aurobindo Pharma Ltd and Cohance Lifesciences Ltd?

As of July 17, 2025, the Aurobindo Pharma Ltd stock price is INR ₹1152.9. On the other hand, Cohance Lifesciences Ltd stock price is INR ₹1062.4.

How do dividend payouts of Aurobindo Pharma Ltd and Cohance Lifesciences Ltd compare?

To compare the dividend payouts of Aurobindo Pharma Ltd and Cohance Lifesciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions